Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Metabolic Health: The Interplay between NAFLD, MAFLD, MASLD and Cardiovascular...
share announcement

Metabolic Health: The Interplay between NAFLD, MAFLD, MASLD and Cardiovascular Disease

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 26 January 2025 | Viewed by 2447

Special Issue Editors

Dr. Marcin Kosmalski

E-Mail
Guest Editor
Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland
Interests: non-alcoholic fatty liver disease; metabolic-associated fatty liver disease; diabetes; clinical pharmacology
Special Issues, Collections and Topics in MDPI journals
Dr. Monika Różycka-Kosmalska

E-Mail
Guest Editor
Department of Electrocardiology, Medical University of Lodz, 92-213 Lodz, Poland
Interests: arrhythmias; intensive cardiac therapy; metabolic disease

Special Issue Information

Dear Colleagues,

Non-alcoholic fatty liver disease (NAFLD), metabolic-dysfunction-associated fatty liver disease (MAFLD), and metabolic-dysfunction-associated steatotic liver disease (MASLD) are some of the most common liver diseases, currently estimated to affect 38% of the global population. NAFLD, MAFLD, and MASLD have different diagnostic definitions and differ in terms of clinical and histological features; however, in everyday medical practice, they all constitute significant medical problems. Their presence is associated with the risk of serious consequences, both in the liver and the cardiovascular system (i.e., CVD). There is a close relationship between NAFLD, MAFLD, and MASLD and CVDs such as hypertension, coronary artery disease, cardiac arrhythmia, and structural heart disease. For this reason, the mentioned liver diseases are classified as the main risk factors for damage to the cardiovascular system. This relationship may be direct or indirect, related to, among others, excess body weight, type 2 diabetes, dyslipidemia, and chronic kidney disease. However, it should be emphasized that there are numerous controversies regarding the diagnostic and therapeutic process of NAFLD/MAFLD/MASLD. They concern the selection of the optimal diagnostic tool as well as an effective therapeutic option that would reduce liver fat and prevent CVD. Despite the proven epidemiological relationship, there is a lack of data on the risk factors for the development of CVD in this group of patients, knowledge of the pathomechanisms leading to this relationship, and therapeutic options, including the treatment and prevention of CVD in patients with NAFLD/MAFDL/MASLD. From a clinical point of view, this issue should be a medical priority due to the frequency of the problem, the presence of numerous controversies, and, above all, the health consequences. Therefore, the aim of our Special Issue will be to answer questions about the relationship between NAFLD, MAFLD, MASLD, and CVD, with particular emphasis on epidemiological data, etiopathogenesis, diagnostic problems, and therapeutic possibilities.

Dr. Marcin Kosmalski
Dr. Monika Różycka-Kosmalska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-alcoholic fatty liver disease (NAFLD)
  • metabolic-dysfunction-associated fatty liver disease (MAFLD)
  • metabolic-dysfunction-associated steatotic liver disease (MASLD)
  • cardiovascular disease (CVD)
  • cardiac arrhythmias
  • structural heart disease
  • coronary artery disease
  • hypertension

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 785 KiB  
Article
Relationship of the Degree of Sarcopenia with the Severity of Nonalcoholic Fatty Liver Disease and Cardiometabolic Risk in Adolescents
by Yoowon Kwon, Jin A Chung, You Jin Choi, Yoo Min Lee, So Yoon Choi, In Hyuk Yoo, Tae Hyeong Kim and Su Jin Jeong
Life 2024, 14(11), 1457; https://doi.org/10.3390/life14111457 - 10 Nov 2024
Viewed by 437
Abstract
The association between nonalcoholic fatty liver disease (NAFLD) and sarcopenia has been suggested. We investigated sarcopenia’s impact on NAFLD severity and its relationship with cardiometabolic risk in adolescents. We conducted a retrospective study on 122 patients aged 13–18 years and diagnosed with both [...] Read more.
The association between nonalcoholic fatty liver disease (NAFLD) and sarcopenia has been suggested. We investigated sarcopenia’s impact on NAFLD severity and its relationship with cardiometabolic risk in adolescents. We conducted a retrospective study on 122 patients aged 13–18 years and diagnosed with both NAFLD and sarcopenia by laboratory tests, abdominal ultrasound (US), and multifrequency bioelectrical impedance analysis. Sarcopenia was stratified into tertiles based on the skeletal muscle-to-fat ratio (MFR), NAFLD severity was established by the US, and cardiometabolic risk was assessed by the triglyceride–glucose (TyG) index and the atherogenic index of plasma (AIP). Compared with the other patients, those in the lower MFR tertiles exhibited a greater severity of NAFLD (p < 0.001) and significantly higher TyG index and AIP. The independent effect of MFR was observed to have a negative correlation with the severity of NAFLD (p < 0.001). Based on the aforementioned results, the degree of sarcopenia can be considered as one of the risk factors of severe NAFLD and might be an indicator of cardiometabolic risk in adolescents. Weight training to reach the amount of muscle mass could be included in the treatment strategies to improve or prevent NAFLD in adolescents with sarcopenia. Full article
(This article belongs to the Special Issue Metabolic Health: The Interplay between NAFLD, MAFLD, MASLD and Cardiovascular Disease)
►▼ Show Figures

Figure 1

20 pages, 1202 KiB  
Article
Allelic, Genotypic, and Haplotypic Analysis of Cytokine IL17A, IL17F, and Toll-like Receptor TLR4 Gene Polymorphisms in Metabolic-Dysfunction-Associated Steatotic Liver Disease: Insights from an Exploratory Study
by Sorina-Cezara Coste, Olga Hilda Orășan, Angela Cozma, Vasile Negrean, Teodora Gabriela Alexescu, Mirela Georgiana Perne, George Ciulei, Adriana Corina Hangan, Roxana Liana Lucaciu, Mihaela Iancu and Lucia-Maria Procopciuc
Life 2024, 14(10), 1327; https://doi.org/10.3390/life14101327 - 18 Oct 2024
Viewed by 579
Abstract
(1) Background: Interleukin 17 (IL17) and toll-like receptor 4 (TLR4) elevate the risk of metabolic and liver diseases. (2) Methods: This study’s objective was to explore the association of IL17 and TLR4 gene polymorphisms with MASLD susceptibility and test their effect on serum [...] Read more.
(1) Background: Interleukin 17 (IL17) and toll-like receptor 4 (TLR4) elevate the risk of metabolic and liver diseases. (2) Methods: This study’s objective was to explore the association of IL17 and TLR4 gene polymorphisms with MASLD susceptibility and test their effect on serum IL17 and TLR4 levels. A total of 43 patients with MASLD (MASH/MAFL) and 38 healthy individuals were genotyped for IL17F-A7488G, IL17A-G197A, TLR4-Asp299Gly, and TLR4-Thr399Ile polymorphisms using PCR-RFLP. ELISA methods determined IL17F, IL17A, and TLR4 serum levels. (3) Conclusions: Patients carrying the variant genotypes (A/G + G/G) of IL17-A7448G (OR = 5.25), (G/A + A/A) of IL17-G197A (OR = 10.57), (Asp/Gly + Gly/Gly) of TLR4-Asp299Gly (OR = 3.52), or (Thr/Ile + Ile/Ile) of TLR4-Thr399Ile (OR = 9.87) had significantly increased odds of MASH. Genotype (G/A + A/A) of IL17-G197A was significantly associated with the odds of MAFL (p = 0.0166). Allele A of the IL17-G197A polymorphism was significantly related to increased odds of MAFL (OR = 4.13, p = 0.0133). In contrast, allele A of IL17-G197A (OR = 5.41, p = 0.008), allele Gly of TLR4-Asp299Gly (OR = 3.19, p = 0.046), and allele Ile of TLR4-Thr399Ile (OR = 6.94, p = 0.008) polymorphisms were significantly related to an increased risk of MASH. Allele A of IL17A-G197A, allele Gly of TLR4-Asp299Gly, and allele Ile of TLR4-Thr399Ile gene polymorphisms were significantly associated with the increased odds of MASLD. In patients with MASLD, we found significant influence from the IL17A-G197A gene polymorphism on IL17F levels (p = 0.0343). Full article
(This article belongs to the Special Issue Metabolic Health: The Interplay between NAFLD, MAFLD, MASLD and Cardiovascular Disease)
►▼ Show Figures

Figure 1

14 pages, 1877 KiB  
Article
Exploring the Th2 Response in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Potential Modulator of the Renin-Angiotensin System (RAS) Pathway in Hypertension Development
by Lucía Angélica Méndez-García, Galileo Escobedo, Itzel Baltazar-Pérez, Nydia Angélica Ocampo-Aguilera, José Alfonso Arreola-Miranda, Miguel Angel Cid-Soto, Ana Alfaro-Cruz, Antonio González-Chávez, Aquiles Ranferi Ocaña-Guzmán and Helena Solleiro-Villavicencio
Life 2024, 14(9), 1080; https://doi.org/10.3390/life14091080 - 29 Aug 2024
Viewed by 869
Abstract
Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is alarmingly increasing alongside the cases of obesity worldwide. MASLD is an underestimated metabolic abnormality closely linked with a higher risk of developing systemic arterial hypertension (SAH). However, [...] Read more.
Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is alarmingly increasing alongside the cases of obesity worldwide. MASLD is an underestimated metabolic abnormality closely linked with a higher risk of developing systemic arterial hypertension (SAH). However, the underlying mechanism of association between MASLD and SAH remains unknown. Inflammation may link these two entities by regulating the renin-angiotensin system (RAS). For this reason, in this study, we evaluated the hepatic expression of a cytokine profile and critical molecules in the RAS pathway in patients with morbid obesity and MASLD, both with SAH. We found a statistically significant correlation between ACE levels and the cytokines IL-4, IL-10, and IL-13 of Th2 response. Furthermore, according to a multiple linear regression analysis, the cytokines IL-4 and IL-13 were the best predictors of ACE levels. Moreover, we observed increased hepatic IL-13 expression in patients with morbid obesity, MASLD, and SAH compared to those without SAH. These results allow us to propose, for the first time, that the Th2 response, through regulating the RAS, could play a critical role in developing SAH in individuals with MASLD and obesity. Full article
(This article belongs to the Special Issue Metabolic Health: The Interplay between NAFLD, MAFLD, MASLD and Cardiovascular Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop